Form 4: LENZ Therapeutics Director Receives Stock Option Grant

Director Jeffrey P. George was granted 22,100 stock options in LENZ Therapeutics, Inc. as part of standard compensation.

Summary

• Director Jeffrey P. George received a grant of 22,100 stock options on June 15, 2026.
• The options have an exercise price of $6.63 per share.
• The options are scheduled to expire on June 15, 2036.
• Vesting is set for the earlier of June 15, 2027, or the date of the next annual meeting of stockholders, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Minor dilution of existing shares upon future exercise of the options.

Risks

• Market price volatility could impact the value of the granted options.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on director compensation.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise.

Comparison to Industry Standards

• The grant aligns with standard corporate governance practices for small-cap biotech firms.
• Vesting schedules tied to annual meetings are common for outside directors in the industry.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if options are exercised.

Next Steps

• Vesting of options on June 15, 2027, or the next annual meeting.

Key Dates

Keywords

LENZ Therapeutics, LENZ, Director Compensation, Stock Options, Insider Transaction, Form 4